In May 2019, South Korean President, Moon Jae-in, announced an ‘Innovative Strategy on the Bio-health Industry’. This new strategy for bio-health will provide partnership and collaboration opportunities for Australian companies across various sectors including the commercialisation of research and development (R&D), clinical trials and digital health.
Amid the global trade and tariffs war between China and the US, Asian markets saw a deterioration in M&A activity in 2Q19. In line with the overall trend in the region, private equity activity decreased for the third consecutive quarter.
Macrogen is a precision medicine and biotechnology company based at the Genomic Medicine Institute of the Seoul National University College of Medicine. The majority-stake investment will give Microba access to Macrogen’s global sales and business networks.
Content Types: ArticleRegions & Countries: South KoreaServices: Employment & Immigration
South Korea: Relaxed Policy on Quota Requirements for D-8 Visa – The Korea Immigration Service has relaxed its policy on D-8 visa quota requirements. The quota is used to limit the number of foreign employees a local sponsoring subsidiary may sponsor under a D-8 visa. The quota was previously strictly tied to the amount of foreign-invested capital the local subsidiary had received from the overseas parent company as indicated in its...
Content Types: NewsletterRegions & Countries: South KoreaIndustries: EducationInformation Technology
Mathpresso, a privately held Seoul, South Korea-based AI-driven education platform developer, plans to raise approximately KRW 15bn (USD 13.2m) in its Series B in 2H19 to buckle down on overseas expansion, according to CEOs Ray Lee and Jake Lee.